Advertisement


Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

2024 ASCO Annual Meeting

Advertisement

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Lisa: Kevin, it is such a pleasure to see you. Wonderful work that you've presented at ASCO 2024 from postMONARCH, a very hotly anticipated trial. Can you describe the trial a little bit and kind of the basics of what you found? Kevin: For sure. Thank you, Lisa. There's been this question from a number of randomized phase II trials about the role of sequencing a CDK4/6 inhibitor and switching the endocrine therapy after progression on a CDK4/6 inhibitor. And this is a class of drugs that has really become a gold standard for our patients, and we wanted to know whether we should be continuing or not. And so postMONARCH is a randomized phase III trial, the first phase III trial, the others that we've seen so far were smaller phase II, and it enrolled patients who had a tumor that had progressed on endocrine therapy and CDK4/6 inhibitor, and directly randomized them to fulvestrant with or without abemaciclib. It was placebo-controlled. It was 368 patients. And what we saw, our assumption was that we would see a difference in progression-free survival of about 0.7, and that's what we saw. And there was a statistically significant study demonstrating that there is benefit for some patients for continuing their CDK4/6 inhibitor at the time of progression. Lisa: Well, and I think it was a beautiful study. You guys also looked at some of the other places that we intervene when you get to the second-line, pre-treated settings, specifically patients with PI-3 kinase aberrations, and found the same benefit essentially in them. Kevin: Right. Most of the new targeted therapies that we've had in breast cancer in the advanced setting has been in biomarker-positive patients. Those that have PI3K pathway alterations, so those with ESO-1 mutations. And so in this study, about 85% of patients, we had their baseline ctDNA, their circulating tumor DNA, available and valuable for the Guardant Infinity assay, and we saw regardless of whether a patient had a PI3K alteration, or an ESO-1 mutation, they benefited from the combination. Lisa: Yeah. And it starts to get into the question of what are we going to do with our patients? We have the INAVO120 trial that was also updated, which takes CDK4/6 inhibitors. It adds PI-3 kinase inhibitors. Now with fulvestrant, this suggests that if patients who has had a CDK4/6 inhibitor could reasonably continue on it with a change in the endocrine therapy, or particularly those who have a PI-3 kinase pathway aberration could go on to a drug targeting those. How do your findings inform that decision? Kevin: Right. We have two drugs that we can give to patients who have PI3K mutations, and with capivacertib, it's more broad than that if you have PTEN or AKT alterations as well. And we see a benefit in this study regardless of whether you have a PI3K mutation, and so this offers another potential strategy for our patients. I would keep in mind that there are some toxicities that we can see with some patients with PI3K targeted agents right now, including hyperglycemia, also some diarrhea. And so in the real world, when we have patients that may have uncontrolled diabetes or may have a high hemoglobin A1C, this offers another potential option for them post-CDK4/6 inhibition. The other thing that I will say is this is the world that we are living in at ASCO 2024. There were a number of new endocrine therapies that are coming down the pike, specific CDK inhibitors, specific PI3K inhibitors, and this is a rapidly evolving field. I think just with this study, we proved the strategy. Lisa: Yeah, that's an incredibly important point because the truth is that this is an adjunctive drug. You're adding it to endocrine therapy. The PI-3 kinase, AKT targeted are also adjunctive added to endocrine therapy. As we have more endocrine therapy backbones, the ability to use these is going to be super important in subsequent lines in patients who have persistently endocrine-sensitive disease. Kevin: For sure. I mean, I think for our patients who have hormone receptor positive HER2-negative advanced disease, I describe to patients this is a marathon. We want patients to remain on well-targeted therapies for as long as we can before they need infusions, before they need to spend more time with us getting intravenous treatments. And so- Lisa: Chemo. Kevin: Chemo. Chemo. Exactly. Lisa: That's terrific. Well, congratulations on a wonderful trial and really thought-provoking results. You've been great. Thanks, Kevin. Kevin: Thanks, Lisa.

Related Videos

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Pancreatic Cancer

Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach

Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).

Clifford A. Hudis, MD: A Message From ASCO’s CEO

Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.

Lymphoma

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.

Advertisement

Advertisement




Advertisement